Drug Approval | December 26, 2023
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
US FDA approval based on NEURO-TTRansform Phase III results
US FDA approval based on NEURO-TTRansform Phase III results
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Subscribe To Our Newsletter & Stay Updated
